Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi, GSK India Units To Join In Promoting Japan Makers’ Drugs

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo India Pharma and GlaxoSmithKline India plan a joint operation to promote the Japanese subsidiary's Benicar (olmesartan medoxomil) drug for treating hypertension. The deal for marketing Daiichi's $2 billion drug also includes promotion of the Japanese firm's combination products. Earlier, the U.K.-based GSK reached a similar agreement with Japan's Astellas to market its Mycamine (micafungin), all part of GSK's strategy of in-licensing products in high-growth therapeutic areas. The deal with GSK India also gives Daiichi an entry into the Indian market, which Daiichi Sankyo India plans to exploit. (Click here for more

You may also be interested in...

Siemens Healthineers Gets Varian In $16.4Bn Deal To Enter Cancer Treatment Market

In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.

Coronavirus Update: Russia Plans First Vaccinations In October

Concern and skepticism about Russia's rapid vaccine roll-out. Meanwhile Japan is latest to reach reaches deal with Pfizer/BioNTech.

Sun Loses Shine In Q1, Testing Times In US

Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts